Conjugated estrogens

Conjugated estrogens

Premarin

Conjugated estrogens drug class

estrogen hormone

Conjugated estrogens dosage form

oral: tablet

Conjugated estrogens ON label indication

1. Abnormal vasomotor function (menopause), genitourinary syndrome of menopause, postmenopausal osteoporosis prophylaxis, female hypogonadism syndrome

2. Primary ovarian failure

3. Acute treatment of abnormal uterine bleeding, hemodynamically stable

Conjugated estrogens OFF label indication

none

Conjugated estrogens MOA

Estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. The primary source of estrogen in normally cycling adult women is the ovarian follicle. After menopause, most endogenous estrogen is produced by conversion of androstenedione to estrone by peripheral tissues. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), through a negative-feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.

Conjugated estrogens box warning

Breast cancer, cardiovascular disease, endometrial cancer, dementia risks, risk versus benefit

Conjugated estrogens contraindication

Hypersensitivity, undiagnosed abnormal genital bleeding, history of estrogen- or progesterone-dependent neoplasia, active or history of DVT or PE, severe liver dysfunction, known or suspected pregnancy, known thrombophilic disorders (eg, protein C or S deficiency), stroke or MI history, estrogen receptor positive neoplasm

Conjugated estrogens pregnancy/breastfeeding

Contraindicated/No human data—probably compatible

Conjugated estrogens adverse effects

1. Abdominal pain

2. breast pain

3. disorder of menstruation

4. headache

5. migraine

6. weight change